Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GHDX [NASD]
Genomic Health Inc.
Index- P/E- EPS (ttm)-0.89 Insider Own1.50% Shs Outstand31.72M Perf Week0.89%
Market Cap1.04B Forward P/E- EPS next Y-0.51 Insider Trans2.37% Shs Float30.99M Perf Month-2.32%
Income-27.70M PEG- EPS next Q-0.21 Inst Own95.70% Short Float9.25% Perf Quarter12.74%
Sales275.40M P/S3.78 EPS this Y-261.50% Inst Trans4.23% Short Ratio19.71 Perf Half Y23.00%
Book/sh4.55 P/B7.22 EPS next Y36.20% ROA-15.70% Target Price31.73 Perf Year-6.25%
Cash/sh3.30 P/C9.95 EPS next 5Y- ROE-19.40% 52W Range23.90 - 37.74 Perf YTD12.16%
Dividend- P/FCF- EPS past 5Y5.90% ROI-8.80% 52W High-13.01% Beta0.58
Dividend %- Quick Ratio4.30 Sales past 5Y18.80% Gross Margin82.90% 52W Low37.36% ATR1.34
Employees684 Current Ratio4.30 Sales Q/Q4.70% Oper. Margin-9.50% RSI (14)48.69 Volatility2.85% 4.53%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-10.10% Rel Volume0.67 Prev Close33.06
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume145.44K Price32.83
Recom2.70 SMA20-4.06% SMA502.70% SMA20015.55% Volume97,003 Change-0.70%
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
Oct-11-11Reiterated RBC Capital Mkts Sector Perform $27 → $21
Oct-05-11Initiated Oppenheimer Perform $20
Feb-09-11Downgrade Ladenburg Thalmann Buy → Neutral
Nov-16-10Initiated Canaccord Genuity Hold $19
Apr-21-10Initiated RBC Capital Mkts Sector Perform
Apr-14-10Initiated William Blair Mkt Perform
Jan-22-10Upgrade Piper Jaffray Neutral → Overweight
Jan-21-10Initiated Jefferies & Co Hold $18
Jan-08-10Initiated ThinkEquity Buy
Jun-11-09Upgrade Thomas Weisel Market Weight → Overweight $23
Oct-08-08Initiated Oppenheimer Perform
Sep-08-08Downgrade Canaccord Adams Buy → Hold $24 → $22
Aug-06-08Reiterated JMP Securities Mkt Outperform $32 → $35
May-07-08Reiterated RBC Capital Mkts Outperform $27 → $26
Nov-19-14 08:00AM  Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact Study To Be Published in European Urology and Urology Practice, Respectively PR Newswire
Nov-14-14 01:04PM  GENOMIC HEALTH INC Financials EDGAR Online Financials
Nov-12-14 06:02PM  Nasdaq stocks posting largest percentage decreases AP -9.37%
Nov-11-14 09:10AM  New Cancer Detection Technique Has Enormous Potential for Life Science Stocks at 24/7 Wall St.
Nov-10-14 04:08PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-08-14 07:07PM  10-Q for Genomic Health, Inc. Company Spotlight
Nov-06-14 05:12PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
01:50PM  Genomic Health Q3 Loss Narrower than Expected, Revenues Lag Zacks
Nov-04-14 06:31PM  Genomic Health beats 3Q profit forecasts AP
04:05PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:02PM  Genomic Health Announces Third Quarter 2014 Financial Results and Reports Continued Growth in U.S. Invasive Breast Cancer Business PR Newswire
09:17AM  Genomic Health (GHDX) Upgraded From Sell to Hold at TheStreet
08:00AM  Genomic Health to Present at the Credit Suisse Annual Healthcare Conference PR Newswire
07:07AM  Q3 2014 Genomic Health Inc Earnings Release - After Market Close CCBN
Oct-28-14 08:00AM  Genomic Health to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 4, 2014 PR Newswire
Oct-15-14 05:52PM  Should Genomic Health (GHDX) Be in Your Portfolio Now? Zacks
Sep-29-14 08:00AM  Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients PR Newswire
Sep-26-14 08:00AM  Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) PR Newswire
Sep-25-14 02:00PM  Genomic Health Upbeat on Strong International Performance Zacks
Sep-24-14 08:00AM  New Survey Reveals Alarming Lack of Understanding of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign with Baseball Hall-of-Famer Joe Torre PR Newswire
Sep-22-14 02:20PM  Is Illumina (ILMN) Worth Adding to Your Portfolio? Zacks
Sep-15-14 02:00PM  Genomic Health Reveals Positive Oncotype DX Test Results Zacks
Sep-12-14 08:00AM  Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics PR Newswire
Sep-09-14 08:00AM  Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress PR Newswire
Aug-20-14 09:45AM  Flatley's Law: How One Company Is Creating Medicine's Genetic Revolution at Forbes
Aug-14-14 11:10AM  Genomic Health Raised to Buy on Better-than-Expected Q2 Zacks
Aug-11-14 08:20AM  Genomic Health Q2 Loss Narrower than Expected, Shares Up Zacks
Aug-08-14 04:36PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08:00AM  Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference PR Newswire
Aug-07-14 04:13PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:02PM  Genomic Health Announces Second Quarter 2014 Financial Results and Business Progress PR Newswire
07:07AM  Q2 2014 GENOMIC HEALTH INC Earnings Release - After Market Close CCBN
Aug-06-14 08:00AM  Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints PR Newswire
06:37AM  Is a Surprise Coming for Genomic Health (GHDX) This Earnings Season? Zacks
Jul-31-14 08:00AM  Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 PR Newswire
Jul-14-14 03:23PM  Is NanoString The Next Illumina In Cancer Diagnostics? at Seeking Alpha
11:00AM  3 Health Care Stocks Primed For Big Moves StreetAuthority Network
Jul-10-14 11:48AM  Show of support for Genomic Health optionMONSTER
Jul-03-14 01:30PM  Genomic Grows on Breast Cancer Test, Margin Pressure Continues Zacks
Jun-19-14 04:16PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jun-12-14 04:02PM  Genomic Health's Oncotype DX Redefines Breast Cancer Therapy Zacks
Jun-11-14 08:00AM  Genomic Health Announces Positive Topline Results of Second Large, Independent Validation Study of Oncotype DX® in DCIS Breast Cancer PR Newswire
Jun-10-14 04:03PM  GENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
03:00AM  Multiple studies presented at 2014 ASCO® annual meeting reinforce unique, practice-changing value of Oncotype DX® breast cancer test Business Wire
Jun-05-14 01:50PM  Genomic Health Up on Fresh Cancer Study Data Zacks
Jun-03-14 08:00AM  Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers PR Newswire
Jun-01-14 09:00AM  Multiple Studies Presented at ASCO® Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX® to Optimize Cancer Care PR Newswire
May-30-14 01:00PM  Genomic Health Posts Fresh Oncotype DX Data Zacks
May-29-14 08:00AM  Oncotype DX® Breast Cancer Test Predicts Late Recurrence Five to 15 Years Out PR Newswire
May-23-14 08:00AM  Genomic Health to Present at Two Upcoming Investor Conferences PR Newswire
May-21-14 01:50PM  Genomic Health: Study Boosts Oncotype DX Again Zacks
May-20-14 05:02PM  Genomic Health announces data reinforcing robustness of Oncotype DX at theflyonthewall.com
04:57PM  Genomic Health Announces Data Reinforcing Robustness of Oncotype DX® Prostate Cancer Test at 2014 American Urological Association (AUA) Annual Meeting PR Newswire
May-19-14 02:20PM  Genomic Health Presents New Oncotype DX Data Zacks
May-16-14 04:03PM  Genomic Health says studies show test predicts prostate cancer aggressiveness at theflyonthewall.com
04:00PM  European Urology Published Groundbreaking Results from Three Studies Demonstrating Genomic Health's Oncotype DX® Test Predicts Prostate Cancer Aggressiveness at Diagnosis PR Newswire
May-14-14 08:00AM  Genomic Health's Oncotype DX® Becomes First Multi-Gene Test for Cancer Management To Be Included in National Institutes of Health's (NIH) Genetic Testing Registry PR Newswire
May-09-14 02:30PM  Q1 Loss Wider than Expected at Genomic Health Zacks
May-07-14 04:08PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report EDGAR Online
May-06-14 04:06PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:02PM  Genomic Health Announces First Quarter 2014 Financial Results and Business Progress PR Newswire
07:07AM  Q1 2014 GENOMIC HEALTH INC Earnings Release - After Market Close CCBN
May-05-14 08:00AM  Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-02-14 08:13AM  Genomic Health reports positive results from Oncotype DX study theflyonthewall.com -5.59%
08:00AM  Oncotype DX® Changes Treatment Decisions in 45 Percent of Stage II Colon Cancer Patients PR Newswire
Apr-29-14 08:00AM  Genomic Health to Announce First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 6, 2014 PR Newswire
Apr-22-14 08:00AM  Global Adoption of Oncotype DX® Breast Cancer Test Continues to Grow with Achievement of Two Significant International Milestones PR Newswire
08:00AM  British Columbia Breast Cancer Patients Gain Access to Oncotype DX® To Help Guide Chemotherapy Treatment Decisions CNW Group
Apr-08-14 02:20PM  Balanced View on Genomic Health Zacks
Apr-03-14 08:13AM  Vipshop Holdings, Genomic Health, Toyota, Honda and Kyocera highlighted as Zacks Bull and Bear of the Day Zacks
01:00AM  Bear of the Day: Genomic Health (GHDX) Zacks
Mar-31-14 04:11PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Mar-20-14 05:15PM  Genomic Health Unveils Oncotype DX Data Zacks
Mar-19-14 08:00AM  Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX® in Europe PR Newswire
Mar-18-14 04:32PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Mar-11-14 04:42PM  GENOMIC HEALTH INC Files SEC form 10-K, Annual Report EDGAR Online
Feb-27-14 07:49AM  Zacks Rank #5 Additions for Thursday Zacks
Feb-13-14 06:38AM  What Makes Genomic Health (GHDX) a Strong Sell? Zacks
Feb-11-14 11:24AM  Commit To Buy Genomic Health At $22.50, Earn 8.4% Annualized Using Options at TheStreet
Feb-07-14 06:20AM  Genomic Health downgraded to Neutral from Outperform at Credit Suisse at theflyonthewall.com
Feb-06-14 06:34AM  Weakness seen in Genomic Health (GHDX): Stock Tumbles 9.0% Zacks
Feb-05-14 11:40AM  Myriad Genetics rallies after buying rival, increasing 2014 outlook at theflyonthewall.com -8.95%
09:30AM  Q4 Loss Narrower Than Expected at Genomic, Revs Up Y/Y Zacks
Feb-04-14 08:10PM  Genomic Health Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
04:09PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi EDGAR Online
04:01PM  Genomic Health Announces Year-End 2013 Financial Results, Provides 2014 Financial Outlook PR Newswire
07:07AM  Q4 2013 GENOMIC HEALTH INC Earnings Release - After Market Close CCBN
Jan-29-14 08:00AM  Genomic Health Announces Results of Oncotype DX® Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium PR Newswire
Jan-28-14 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on Tuesday, February 4, 2014 PR Newswire
Jan-15-14 03:58PM  Illumina's New Low-Cost Genome Machine Will Change Health Care Forever at BusinessWeek
Jan-07-14 08:00AM  Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients PR Newswire
06:50AM  GTX Inc. (GTXI) Worth Watching: Stock Rises 7.2% Zacks
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, facilitating physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as is used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Popovits Kimberly JPresident and CEONov 12Option Exercise18.894,30081,22739,165Nov 14 07:07 PM
Popovits Kimberly JPresident and CEONov 12Sale34.824,300149,70936,965Nov 14 07:07 PM
Cole G BradleyCOONov 10Option Exercise9.394,00037,56026,891Nov 12 04:32 PM
Cole G BradleyCOONov 10Sale35.354,000141,38822,891Nov 12 04:32 PM
LIVINGSTON RANDALL SDirectorNov 03Option Exercise10.733,00032,1909,149Nov 05 05:01 PM
LIVINGSTON RANDALL SDirectorNov 03Sale36.243,000108,7196,149Nov 05 05:01 PM
Popovits Kimberly JPresident and CEOOct 13Option Exercise18.893,00056,67039,965Oct 15 04:22 PM
Popovits Kimberly JPresident and CEOOct 13Sale30.783,00092,32636,965Oct 15 04:22 PM
Cole G BradleyCOOOct 08Option Exercise9.394,00037,56026,891Oct 10 04:19 PM
Cole G BradleyCOOOct 08Sale28.774,000115,09822,891Oct 10 04:19 PM
Popovits Kimberly JPresident and CEOSep 11Option Exercise16.953,00050,84739,965Sep 15 04:16 PM
Popovits Kimberly JPresident and CEOSep 11Sale29.823,00089,44636,965Sep 15 04:16 PM
Shak StevenEVP of R&DAug 14Option Exercise2.886,34818,282318,646Aug 15 05:21 PM
Shak StevenEVP of R&DAug 14Sale27.496,348174,498312,298Aug 15 05:21 PM
Shak StevenEVP of R&DAug 13Option Exercise2.887,00020,160319,298Aug 15 05:21 PM
Shak StevenEVP of R&DAug 13Sale27.257,000190,726312,298Aug 15 05:21 PM
Popovits Kimberly JPresident and CEOAug 12Option Exercise9.393,00028,17039,965Aug 14 04:54 PM
Popovits Kimberly JPresident and CEOAug 12Sale26.073,00078,20136,965Aug 14 04:54 PM
Popovits Kimberly JPresident and CEOJul 14Option Exercise9.393,00028,17039,965Jul 16 04:17 PM
Popovits Kimberly JPresident and CEOJul 14Sale26.593,00079,77736,965Jul 16 04:17 PM
Cole G BradleyCOOJul 08Option Exercise2.882,3006,62425,191Jul 10 04:19 PM
Cole G BradleyCOOJul 08Sale27.052,30062,20922,891Jul 10 04:19 PM
Shak StevenEVP of R&DJul 01Option Exercise2.887,00020,160319,298Jul 03 06:04 PM
Shak StevenEVP of R&DJul 01Sale27.007,000188,970312,298Jul 03 06:04 PM
Popovits Kimberly JPresident and CEOJun 12Option Exercise9.393,00028,17039,965Jun 16 06:03 PM
Shak StevenEVP of R&DJun 12Option Exercise2.887,00020,160319,298Jun 16 06:08 PM
Shak StevenEVP of R&DJun 12Sale26.737,000187,107312,298Jun 16 06:08 PM
Popovits Kimberly JPresident and CEOJun 12Sale26.103,00078,29536,965Jun 16 06:03 PM
Schorno Dean LCFOJun 10Option Exercise18.044,00072,14028,524Jun 13 08:07 PM
Schorno Dean LCFOJun 10Sale27.624,000110,48724,524Jun 13 08:07 PM
Cole G BradleyCOOJun 09Option Exercise2.882,3376,73125,228Jun 11 05:48 PM
Cole G BradleyCOOJun 09Sale27.292,33763,76722,891Jun 11 05:48 PM
Popovits Kimberly JPresident and CEOMay 12Option Exercise9.393,00028,17039,255May 14 04:04 PM
Popovits Kimberly JPresident and CEOMay 12Sale26.543,00079,61736,255May 14 04:04 PM
Schorno Dean LCFOMay 09Option Exercise18.044,00072,14027,814May 13 04:05 PM
Schorno Dean LCFOMay 09Sale25.094,000100,35923,814May 13 04:05 PM
Shak StevenEVP of R&DApr 14Option Exercise2.887,00020,160318,547Apr 16 04:19 PM
Shak StevenEVP of R&DApr 14Sale26.257,000183,734311,588Apr 16 04:19 PM
Cole G BradleyCOOApr 08Option Exercise2.883,0008,64025,226Apr 10 04:20 PM
Cole G BradleyCOOApr 08Sale27.003,00081,00022,226Apr 10 04:20 PM
Shak StevenEVP of R&DMar 14Option Exercise2.887,00020,160318,588Mar 18 05:39 PM
Shak StevenEVP of R&DMar 14Sale28.367,000198,493311,588Mar 18 05:39 PM
Cole G BradleyCOOMar 10Option Exercise2.883,0008,64025,226Mar 12 04:59 PM
Cole G BradleyCOOMar 10Sale27.763,00083,29022,226Mar 12 04:59 PM
HIBBS KATHY LSVP & General CounselFeb 18Sale27.881,31236,58415,787Feb 19 07:16 PM
Shak StevenEVP of R&DFeb 14Option Exercise2.887,00020,160320,643Feb 19 07:11 PM
Shak StevenEVP of R&DFeb 14Sale27.387,000191,630313,643Feb 19 07:11 PM
Cole G BradleyCOOFeb 10Option Exercise2.883,0008,64027,789Feb 12 04:51 PM
Cole G BradleyCOOFeb 10Sale27.003,00081,00024,789Feb 12 04:51 PM
Shak StevenEVP of R&DJan 15Option Exercise2.887,00020,160315,283Jan 17 01:39 PM
Shak StevenEVP of R&DJan 15Sale31.517,000220,601308,283Jan 17 01:39 PM
Popovits Kimberly JPresident and CEOJan 13Option Exercise9.392,50023,47529,366Jan 15 10:26 AM
Popovits Kimberly JPresident and CEOJan 13Sale30.002,50075,00026,866Jan 15 10:26 AM
Shak StevenEVP of R&D & CMODec 17Option Exercise2.887,00020,160315,283Dec 18 01:45 PM
Shak StevenEVP of R&D & CMODec 17Sale29.247,000204,671308,283Dec 18 01:45 PM
Shak StevenEVP of R&D & CMODec 16Option Exercise2.887,00020,160315,283Dec 18 01:45 PM
Shak StevenEVP of R&D & CMODec 16Sale29.917,000209,350308,283Dec 18 01:45 PM
Popovits Kimberly JPresident and CEODec 12Option Exercise9.392,50023,47529,366Dec 16 02:34 PM
Popovits Kimberly JPresident and CEODec 12Sale30.682,50076,70526,866Dec 16 02:34 PM
Schorno Dean LCFODec 09Option Exercise17.233,00051,69024,557Dec 10 04:40 PM
Schorno Dean LCFODec 09Sale33.253,00099,76121,557Dec 10 04:40 PM
LIVINGSTON RANDALL SDirectorDec 02Option Exercise10.731,00010,7307,149Dec 04 05:52 PM
LIVINGSTON RANDALL SDirectorDec 02Sale34.921,00034,9206,149Dec 04 05:52 PM